Top Stories
The European Commission cleared a subcutaneous version of Sanofi's anti-CD38 mAb Sarclisa, while GNI Group bought Ayumi Pharmaceutical for about $280 million.
With Monday's raise, City plans to advance experimental Stargardt disease treatment CITY-RBP4, alongside an undisclosed programme, into the clinic this year.
The company said elecoglipron helped 90% of diabetes patients reach guideline A1c targets while producing meaningful weight loss.
The combined company's $900-million cash runway will fund operations into 2029.
The deal gives it access to Firefly's degrader-antibody conjugate platform, designed to deliver highly selective protein degraders directly to tumour cells while limiting exposure to healthy tissue.
Conference News
COPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest data from its Endocrinology Rare Disease programs in hypoparathyroidism, achon...
Châtillon, France, June 8, 2026DBV Technologies to Present New Positive Data from VITESSE Study and Preview Recently Initiated THRIVE Study at the EAACI Congress 2026In the Phase 3 VITESSE study, VIAS...
After data at the American Diabetes Association (ADA) meeting showed potential utility for Lilly's retatrutide beyond patients requiring the greatest degree of weight loss, are physicians likely to use it more broadly?
Zealand Pharma's stock sank more than 22% on Monday after new data, shared at the American Diabetes Association (ADA) meeting on Sunday, revealed a high rate of study discontinuations in a Phase III t...
Expansions of both new and old programmes at Novo Nordisk have the pharma concentrating on its amylin options as it aims to finally best the rising bar at Eli Lilly.
